Key result
Beta-blocker therapy ≥1 year post-AMI is linked to ~19% lower all-cause mortality versus <1 year.
Why the study?
The association between long-term β-blocker therapy and clinical outcomes in patients without heart failure after acute myocardial infarction was unclear.
Does beta-blocker therapy for ≥1 year reduce all-cause death in patients without heart failure who underwent coronary revascularization for acute myocardial infarction?
Population
28 970 patients without HF after revascularized AMI, event-free for 1 year
Comparison
β-blocker therapy for ≥1 year vs <1 year
Design
Nationwide cohort study with landmark analysis
Authors
Loading...
β-blocker use ≥1 year was associated with lower post-AMI mortality without HF; challenges weak consensus against benefit yet remains hypothesis-generating.
Does beta-blocker therapy for ≥1 year reduce all-cause death in patients without heart failure who underwent coronary revascularization for acute myocardial infarction?
Long-term beta-blocker therapy (≥1 year) after AMI in patients without heart failure is associated with a reduced risk of all-cause death up to 2 years, though the benefit may attenuate beyond 3 years.
Kim et al. (2020) studied this question. β-blocker therapy for ≥1 year after acute myocardial infarction was associated with a 19% lower risk of all-cause death (HR 0.81) compared to <1 year treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: